Skip to main content
TipRanks
Go Ultimate75% OFF

Krystal Biotech (4KB) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

4KB Analyst Ratings

Strong Buy
6Ratings
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to Krystal Biotech in the past 3 months

4KB Stock 12 Month Forecast

€355.39▲(29.23% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is EUR 355.39 with a high forecast of EUR 398.63 and a low forecast of EUR 326.32. The average price target represents a 29.23% change from the last price of EUR 275.00.
Highest Price Target€398.63Average Price Target€355.39Lowest Price Target€326.32

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:4KB
Price TargetArticle
RBC Capital€338.97buy23.26%UpsideReiterated11/06/26
Citi€376.03→€372.42buy35.43%UpsideReiterated11/03/26
TD Cowen€364.28→€343.49buy24.91%UpsideReiterated11/03/26
H.C. Wainwright€326.32buy18.66%UpsideReiterated11/02/26
Bank of America Securities€361.57→€352.53buy28.19%UpsideReiterated11/02/26
Goldman Sachs€398.63buy44.96%UpsideInitiated09/24/26
Wolfe Research―hold―Reiterated08/11/26
William Blair―buy―Reiterated08/03/26
Jefferies€428.46buy55.80%UpsideAssigned07/13/26
Evercore ISI€266.66→€271.18buy-1.39%DownsideReiterated05/05/26
Clear Street€305.53→€281.12buy2.23%UpsideReiterated05/04/26
Chardan Capital€291.97buy6.17%UpsideReiterated05/04/26
Guggenheim€256.72buy-6.65%DownsideReiterated05/04/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PLSEPulse Biosciences
SLDBSolid Biosciences
RZLTRezolute
IMUXImmunic
MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Krystal Biotech

3 Months
Geulah Livshits
Geulah LivshitsChardan Capital
Success Rate13/20 ratings generated profit
65%
Average Return
+11.04%

Copying Geulah Livshits's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +11.04% per trade.

1 Year
Geulah Livshits
Geulah LivshitsChardan Capital
Success Rate19/20 ratings generated profit
95%
Average Return
+47.67%

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +47.67% per trade.

2 Years
Geulah Livshits
Geulah LivshitsChardan Capital
Success Rate20/20 ratings generated profit
100%
Average Return
+92.75%

Copying Geulah Livshits's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +92.75% per trade.

4KB Analyst Recommendation Trends

010203040Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 4KB
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy00000
Buy2012111212
Hold01110
Sell00000
Strong Sell00000
total2013121312

In the current month, 4KB has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4KB average Analyst price target in the past 3 months is 355.39.

4KB Financial Forecast

€0€0.75€1.5€2.25€3Q1 2026Q3 2026Q4 2026
High€2.17
Consensus€1.83
Low€1.61

4KB Earnings Forecast

Next quarter’s earnings estimate for 4KB is EUR 1.83 with a range of EUR 1.61 to EUR 2.17. The previous quarter’s EPS was EUR 1.84. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€96.1M€102.8M€109.6M€116.3M€123.1MQ1 2026Q3 2026Q4 2026
High€123M
Consensus€120M
Low€116M

4KB Sales Forecast

Next quarter’s sales forecast for 4KB is EUR 120.19M with a range of EUR 116.28M to EUR 123.08M. The previous quarter’s sales results were EUR 114.20M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

4KB Stock Forecast FAQ

What is DE:4KB’s average 12-month price target, according to analysts?
Based on analyst ratings, Krystal Biotech’s 12-month average price target is €355.39.
What is DE:4KB’s upside potential, based on the analysts’ average price target?
Krystal Biotech has 29.23% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Krystal Biotech a Buy, Sell or Hold?
Krystal Biotech has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Krystal Biotech’s share price target?
The average share price target for Krystal Biotech is €355.39. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €398.63, and the lowest forecast is €326.32. The average share price target represents a 29.23% increase from the current price of €275.
What do analysts say about Krystal Biotech?
Krystal Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of Krystal Biotech?
To buy shares of DE:4KB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.